Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created so. In some cases, forward-looking statements can be identified by words such as may, will, may, may, should, expect, plan, anticipates, intends, believe , estimate, anticipate, potential or other similar terms. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. Although the Company believes that these assumptions expectations, estimates and projections reasonable, these statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the control of the Company. These and other important factors, including those discussed under Risk Factors in our Form 10-K for the year ended June 26, 2010, and subsequent filings of the Company with the Securities and Exchange Commission, could cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this press release are made only on the date hereof and, except as otherwise provided by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or another.Perrigo Chairman and CEO Joseph C. Dad said, This approval is another example of Perrigo to expand our portfolio of generic Rx range of information products and bring new products to market. Perrigo is working every day to make quality care more accessible.
About 200 million people around the world are expected to suffer from hepatitis C, of which about 3.2 million people with chronic infection in the United States. Many do not know they are infected again with liver disease that causes damage, which means they can pass on to others without realizing it.
The product is the generic equivalent of Graceway Pharmaceuticals Aldara Cream, 5 percent, a topical treatment for actinic keratosis of, basal cell carcinoma of the face or scalp, and external genital and perianal warts in patients 12 years or more.
Aldara had a turnover of around 382 million dollars before the formation of the generics market, as measured by Wolters Kluwer Health.